<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03824366</url>
  </required_header>
  <id_info>
    <org_study_id>201901172</org_study_id>
    <nct_id>NCT03824366</nct_id>
  </id_info>
  <brief_title>Same-session MR-only Simulation and Treatment With MRI-guided Adaptive Palliative RadioTherapy</brief_title>
  <acronym>MAP-RT</acronym>
  <official_title>Pilot Study of Same-session MR-only Simulation and Treatment With MRI-guided Adaptive Palliative RadioTherapy (MAP-RT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This proposed study is unique in that patients will not undergo computed tomography (CT)
      simulation at any point during their treatment course and will instead have same-session
      magnetic resonance (MR)-only simulation and treatment planning, on-table, using the adaptive
      radiotherapy (ART) workflow. In this manner, patients requiring urgent treatment could
      initiate treatment as early as the day of initial radiation oncology consultation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 23, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of same-session MRI-only simulation as measured by the number of participants who receive at least 70% of their scheduled treatment fractions on the first on-table attempt for each respective fraction</measure>
    <time_frame>Completion of enrollment (approximately 1 year)</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Malignancy</condition>
  <condition>Metastasis</condition>
  <condition>Hemoptysis</condition>
  <condition>Gastrointestinal Bleeding</condition>
  <condition>Pelvic Bleeding</condition>
  <condition>Superior Vena Cava Syndrome</condition>
  <condition>Mediastinal Disease</condition>
  <arm_group>
    <arm_group_label>Volumetric MR imaging planning</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will undergo volumetric MR imaging on treatment days in positioning appropriate for the specific treatment site.
Patients will receive standard of care palliative radiation therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Volumetric MR imaging</intervention_name>
    <description>This will most frequently be supine with arms positioned so not in the way of treatment beams.</description>
    <arm_group_label>Volumetric MR imaging planning</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation therapy</intervention_name>
    <description>-Standard of care</description>
    <arm_group_label>Volumetric MR imaging planning</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of malignancy (biopsy proven or high clinical suspicion with urgent/emergent
             clinical indications for palliative RT)

          -  Requires delivery of palliative radiation therapy for the treatment of painful
             metastasis, hemoptysis, gastrointestinal bleeding, pelvic bleeding, or superior vena
             cava syndrome/bulky mediastinal disease.

          -  At least 18 years of age.

          -  Able to understand and willing to sign an IRB-approved written informed consent
             document.

        Exclusion Criteria:

          -  Pregnant. Patients of childbearing potential must have a negative pregnancy test
             within 14 days of study entry.

          -  Medical contraindication to undergoing MR imaging.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyun Kim, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyun Kim, M.D.</last_name>
    <phone>314-362-8502</phone>
    <email>kim.hyun@wustl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyun Kim, M.D.</last_name>
      <phone>314-362-8502</phone>
      <email>kim.hyun@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Hyun Kim, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Soumon Rudra, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lauren Henke, M.D., MSCI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olga Green, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 29, 2019</study_first_submitted>
  <study_first_submitted_qc>January 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2019</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Hemorrhage</mesh_term>
    <mesh_term>Hemoptysis</mesh_term>
    <mesh_term>Mediastinal Diseases</mesh_term>
    <mesh_term>Superior Vena Cava Syndrome</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures and appendices). Participants who opted out of data sharing in the informed consent will not be included.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Beginning 3 months and ending 5 years following article publication</ipd_time_frame>
    <ipd_access_criteria>Researches must provide a methodologically sound proposal. Proposals should be directed to kim.hyun@wustl.edu. To gain access, data requestors will need to sign a data access agreement and provide proof of appropriate regulatory approvals as necessary.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

